ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2755

Disease Activity and Quality of Life in BEHÇET’S Disease: The Role of Patients Reportedoutcomes

Elena Elefante1, Rosaria Talarico2, Chiara Stagnaro3, Anna d'Ascanio4, Antonio Tavoni5, Chiari Tani1, Chiara Baldini1, Marta Mosca6 and Stefano Bombardieri2, 1University of Pisa, Rheumatology Unit, Pisa, Italy, 2Rheumatology Unit, Pisa, Italy, 3Rheumatology Unit, University of Pisa, Pisa, Italy, 4Internal Medicine, University of Pisa, Pisa, Italy, 5University of Pisa, Immunoallergology Unit, Pisa, Italy, 6V. Roma 67, 56126 Pisa, S. Chiara, Pisa, Italy

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Behcet's syndrome and outcome measures

  • Tweet
  • Email
  • Print
Session Information

Title: Vasculitis

Session Type: Abstract Submissions (ACR)

Background/Purpose

Behçet’s disease (BD) is a systemic vasculitis, typically characterised by recurrent oro-genital ulcers, ocular inflammation and skin manifestations; articular, vascular, gastro-enteric and neurological involvement may also occur. Since BD has a chronic-relapsing course and it can be very severe, debilitating and potentially life-threatening, it may without any doubt affect the quality of life of the patients. Moreover, it is well known that patient’s perception of own disease represents an useful tool to help physicians to improve the understanding and management of the disease itself. The primary aim of this study was to explore the role of quality of life patients reported outcome (PRO) in better identifying the global status of BD.

Methods

The study enrolled 120 patients, all fulfilling the International Study Group (ISG) criteria for BD. The male/female ratio was 1.6:1, with a mean disease duration of 11±6 years. Their mean age was 42±8 years (min:18, max:77), while the mean age at disease onset was 24±5 years. The primary end-point was to study any potential correlation between quality of life and disease activity. Disease activity was evaluated by means of the Behçet’s Disease Current Activity Form (BDCAF), while the Italian version of the Short-form-36 (SF-36) was used to evaluate quality of life. Disease activity was compared with the global SF-36 score and with each dimension, that includes: physical functioning, physical disability, body pain, general health, vitality, social functioning, emotional disability, mental health. The statistical analysis was performed using Student t-test, Mann-Whitney-U test, ANOVA and Pearson correlation

Results

At time of evaluation, according BDCAF, 47 BD patients (39%) had clinically active disease (18 ocular involvement, 8 joint involvement, 4 neurological involvement, 2 gastro-enteric, 15 muco-cutaneous involvement). As expected, the overall SF-36 scores were significantly lower in patients with clinically active disease. Moreover, female BD patients had statistically significant lower scores in all SF-36 domains compared with male patients. When each domain of SF-36 was evaluated, we found that physical disability (p=0.004), body pain (p=0.006), general health (p=0.001), and vitality (p=0.001) were significantly lower in patients with disease activity. Notably, vitality (p=0.001), physical disability(p=0.004), social functioning (p=0.001), emotional disability (p=0.003) and mental health (p=0.001) were significantly lower in patients with muco-cutaneous active disease, compared with the other patients with active disease.

Conclusion

The clinicians who take care of any chronic disease would like to correctly know the current status of a patient to manage him properly. In this regard, the combination data of PRO measures and disease activity have been demonstrated to add more information compared to the evaluation of disease activity alone. These consideration suggest that the correct assessment of BD need a multi-dimensional approach, that fairly includes disease activity, disease damage and quality of life


Disclosure:

E. Elefante,
None;

R. Talarico,
None;

C. Stagnaro,
None;

A. d’Ascanio,
None;

A. Tavoni,
None;

C. Tani,
None;

C. Baldini,
None;

M. Mosca,
None;

S. Bombardieri,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/disease-activity-and-quality-of-life-in-behcets-disease-the-role-of-patients-reportedoutcomes/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology